SYNTHESIS OF 2,3,4,5-TETRAHYDRO-1*H*-2-BENZAZEPINES *VIA* PUMMERER-TYPE CYCLIZATION OF *N*-ARYLMETHYL-*N*-(3-PHENYLSULFINYLPROPYL)FORMAMIDES

Yoshie Horiguchi, Toshiaki Saitoh, Sachiko Terakado, Konomi Honda, Tomoko Kimura, Jun Toda, and Takehiro Sano*


Showa Pharmaceutical University, 3-3165, Higashi-tamagawagakuen, Machida, Tokyo 194-8543, Japan

Abstract A construction of 1*H*-benzazepine ring system was achieved *via* a modified Pummerer reaction of *N*-arylmethyl-*N*-(3-phenylsulfinylpropyl)-formamides (**5**) using trifluoroacetic acid and borontrifluoride etherate. This method provides an effective synthesis of 7,8-dimethoxy-2,3,4,5-tetrahydro-1*H*-2-benzazepine (**10a**), the synthetic intermediate of capsazepine (**1**), an antagonist of capsaicin and resinferatoxin.

It is well known that the *in situ* formed thionium ion generated under the acidic conditions from a sulfinyl precursor (Pummerer reaction) is a powerfull electrophilic group reacting efficiently with nucleophilic carbon species such as alkenes, aromatics and enol ethers.¹ This reaction was successfully applied for the synthesis of various carbocycles and heterocycles.² Recently, we explored the reaction and used it as the key strategy for the syntheses of 1,2,3,4-tetrahydroisoquinolines,³ 1,2,3,4-tetrahydroquinolines,⁴ erythrinan,⁵ isopavine and pavine alkakoids,⁶ 2-quinolones,⁷ and 2,3,4,5-tetrahydro-1*H*-3-benzazepines.⁸


In these studies we have found that the cyclization under a usual Pummerer condition using trifluoroacetic anhydride (TFAA) as a sole reagent highly effectively proceeds at room temperature when the aromatic ring is sufficiently electron-rich (method A).^{3,4} On the other hand in the substrates lacking an electron donating substituent on the aromatic ring the method A does not induce the cyclization unless boron trifluoride diethyl etherate (BF₃•Et₂O) is used as an additive reagent.^{3a-c,4} This method using TFAA and BF₃•Et₂O (method B) seems to be effective for the cyclization of a weak nucleophilic aromatic π -bond. In this paper we described the synthesis of 2,3,4,5-tetrahydro-1*H*-2-benzazepine *via* cyclization using

Pummerer reaction and an application to the synthesis of capsazepine (1), an antagonist of the sensory neuron excitants capsaicin and resinferatoxin.⁹



Preparation of Sulfoxides


The sulfoxides (5), substrates of Pummerer reaction, were prepared from aromatic aldehydes (2) and 3-phenylsulfanylpropylamine⁴ as follows. Condensation of 2 with the amine in EtOH in the presence of



acetic acid followed by NaBH₄ reduction of the resulting imine afforded *N*-arylmethyl-3phenylsulfanylpropylamines (**4**) in good yields. The amines (**3**) were protected by formylation and the resulting formamides (**4**) were oxidized with sodium metaperiodate (NaIO₄) in aqueous methanol to produce **5** in excellent overall yields. The products (**3**), (**4**), and (**5**) were well characterized by MS, IR, and ¹H- and ¹³C-NMR spectral data (See Experimental).

Pummerer Reaction (method A)

A solution of **5** in benzene was treated with TFAA at room temperature for appropriates times under an argon atmosphere (method A condition). Sulfoxide (**5a**) yielded 5-phenylsulfanylbenzazepine (**6a**) in moderate yield (56%) accompanied with vinyl sulfide (**7a**) as an uncyclized product (31%). The sulfoxide (**5b**) produced the corresponding benzazepine (**6b**) in yield of only 13%, although the aromatic ring is electronically activated by two OMe groups positioned at *para* and *ortho*. In this case no other products were characterized. The reaction of **5c** having two OMe groups at *ortho*- and *meta*-positions yielded no cyclized product. Furthermore, the sulfoxide (**5d**) having a *para* OMe group afforded the corresponding benzazepine (**6d**) in 13% yield. Other monomethoxy sulfoxides (**5e-5f**) having a *meta* OMe group and



sulfoxide (5g) with no OMe group, when treated with TFAA, merely yielded complex mixtures. No benzazepines could be obtained in any extent.

Pummerer Reaction (method B)

The cyclization of sulfoxides (5) was examined under the method B conditions. A solution of 5a in benzene was treated with TFAA for 45 min at room temperature, then $BF_3 \cdot Et_2O$ was added and the mixture was allowed to react for further 45 min, giving the benzazepine (6a) in 66% yield and 4a in 5% yield. Thus, the yield of 6a was comparable to that achieved by method A. In the cases of 5b, 5c, and 5d use of $BF_3 \cdot Et_2O$ as an additive improved the ring closure reaction to give 6b, 6c, and 6d in moderate yields as shown in the Table. However, the reactions of 5e-g on the similar treatment under method B conditions did not caused the desired cyclization in any extent. The sulfoxides (5e) and (5f) only gave the bis-phenylsulfanyl derivative (8e) and (8f) respectively.

		Condition	Yield (%)				
sulfoxide (5)	Reagent	Additive	Time	PheS-bebzazepine		Others	
5a	TFAA	non	4	(6a)	56	(7a)	31
5a	TFAA	$BF_3 \cdot Et_2O$	1.5	(6a)	66	(4 a)	5
5b	TFAA	non	2	(6b)	13		
5b	TFAA	BF ₃ ·Et ₂ O	1	(6b)	61		
5c	TFAA	non	12	(6c)	b)		
5c	TFAA	BF ₃ ·Et ₂ O	4	(6c)	45		
5d	TFAA	non	18	(6d)	13		
5d	TFAA	BF ₃ ·Et ₂ O	3	(6d)	78		
5e	TFAA	$BF_3 \cdot Et_2O$	4			(8 e)	21
5 f	TFAA	$BF_3 \cdot Et_2O$	3			(8f)	33
5g	TFAA	BF ₃ ·Et ₂ O	24		b)		

TablePummere Reaction of Sulfoxides (5)

a) In benzene at room temperature, b) No characterizable products

The results summarized in the Table indicated that the formation of benzazepine ring by Pummerer

reaction of **5** occurred under method B conditions if the nucleophilic center of the aromatic ring is activated by electron donating group such as OMe group, although this cyclization leading to benzazepine ring, particularly under method A conditions, was much less effective when compared with that of *N*-aryl-*N*-arylmethyl-*N*- (3-phenylsulfinylethyl)formamide leading to 1,2,3,4-tetrahydroisoquinoline ring.⁴

Preparation of Benzazepines

Reductive removal of the phenylsulfanyl group readily proceeded on treatment with NiCl₂-NaBH₄ in MeOH-THF to give *N*-formyl-benzazepines (9) in good yields. Deprotection of the *N*-formyl group was achieved by conventional methods. Alkaline hydrolysis gave the benzazepines (10). Reduction of 9 with LiAlH₄ gave *N*-methylbenzazepines (11).

The synthesis using this route provides 7,8-dimethoxy- (10a), 6,8-dimethoxy- (10b), 6,9-dimethoxy- (10c), 8-methoxy-2,3,4,5-tetrahydro-1*H*-2-benzazepine (10d), and their *N*-methyl derivatives (11) in moderate overall yields. 7,8-Dimethoxy derivative (10a) is the synthetic precursor of capsazepine (1).^{9,10}

EXPERIMENTAL

General Notes Unless otherwise noted, the following procedures were adopted. Melting points were taken on a Yanagimoto SP-M1 hot-stage melting point apparatus and are uncorrected. IR spectra were obtained as films for oils and gums, and KBr disks for solids with a JASCO FT/IR-5000 spectrometer, and are given in cm⁻¹. NMR spectra were measured on a JEOL JNM-AL 300 (¹H-NMR, 300 MHz; ¹³C-NMR, 75 MHz) NMR spectrometer in CDCl₃ with tetramethylsilane as an internal standard at room temperature and the chemical shifts are given in δ values. LR-MS were taken on JMS-AM20, and high resolution MS (HR-MS) on a JEOL JMS-D300 spectrometer at 70 eV [electron ionization MS (EI-MS)] or at 270 eV [chemical ionization (CI-MS)], reactant gas: *iso*-butane) using direct or GC/MS inlet systems. Elemental analyses were recorded on a Yanaco-CHN-corder MT-3. Thin layer chromatography (TLC) was performed on Merck precoated Silica gel 60 F₂₅₄ plates (Merck).

Column chromatography was carried out with silica gel (Wakogel C-200). The organic extract from each reaction mixture was washed with brine, dried over anhydrous Na₂SO₄, and concentrated *in vacuo* to dryness.

Preparation of N-(3,4-Dimethoxyphenyl)methyl-(3-phenylsulfanyl)propylamine (3a). Typical

Procedure. A solution of 3,4-dimethoxybenzaldehyde (**2a**) (1.19 g, 7.2 mmol), 3-phenylsulfanylpropylamine (1.2 g, 7.2 mmol)⁴ and acetic acid (5.184 g, 8.64 mmol) in EtOH (250 mL) was refluxed for 23 h. NaBH₄ (272 mg, 7.2 mmol) was added slowly to a reaction mixture at 0°C and stirred for 30 min at rt. Water was added to the reaction mixture. After removal of the solvent *in vacuo*, the residue was extracted with CHCl₃. The residual oil was purified by column chromatography with ethyl acetate to give **3a** (1.40g, 74%) as a yellow oil. IR (film): 3316, 1590. ¹H-NMR: 1.9-2.2 (2H, m, -NHCH₂CH₂CH₂SPh), 2.7-3.1 (4H, m, -NHCH₂CH₂CH₂SPh and -NHCH₂CH₂CH₂SPh), 3.83 (3H, s, OMe), 3.90 (2H, s, -NHCH₂Ar), 3.92 (3H, s, OMe), 6.7-7.0 (3H, m, ArH), 7.1-7.4 (5H, m, SPh). ¹³C-NMR: 25.6 (t), 31.0 (t), 44.7 (t), 50.8 (t), 55.8 (q), 56.2 (q), 110.9 (d), 112.8 (d), 122.6 (d), 123.4 (s), 126.3 (d), 129.0 (dx2), 129.6 (dx2), 135.3 (s), 149.3 (s), 149.5 (s). LRMS *m/z*: 317 (M⁺).

N-(3,5-Dimethoxyphenyl)methyl-(3-phenylsulfanyl)propylamine (3b): From 3,5-dimethoxybenzaldehyde (2b) (1.19 g, 7.2 mmol) and 3-phenylsulfanylamine (1.2g, 7.2 mmol);column chromatography with ethyl acetate gave 3b (1.50 g, 79%) as a pale yellow oil. IR (film): 3311, 1596. ¹H-NMR: 1.82 (2H, quintet, *J*=7 Hz, -NHCH₂C<u>H</u>₂CH₂SPh), 2.75 (2H, t, *J*=7 Hz, -NHCH₂CH₂C<u>H</u>₂SPh), 2.99 (2H, t, *J*=7 Hz, -NHC<u>H</u>₂CH₂CH₂SPh) 3.71 (2H, s, -NHC<u>H</u>₂Ar), 3.78 (6H, s, OMex2), 6.3-6.5 (3H, m, ArH), 7.1-7.4 (5H, m, SPh). ¹³C-NMR: 29.4 (t), 31.4 (t), 47.9 (t), 53.9 (t), 55.2 (qx2), 98.9 (d), 105.8 (d), 125.7 (dx2), 128.8 (dx2), 129.0 (dx2), 136.5 (s), 142.8 (s), 160.8 (s). 160.9 (s). LRMS *m/z*: 317 (M⁺).

N-(2,5-Dimethoxyphenyl)methyl-(3-phenylsulfanyl)propylamine (3c): From 2,5-dimethoxybenzaldehyde (2c) (1.19 g, 7.2 mmol) and 3-phenylsulfanylamine (1.2g, 7.2 mmol); column chromatography with ethyl acetate gave 3c (1.90 g, 92%) as a yellow oil. IR (film): 3320, 1586.

¹H-NMR: 1.83 (2H, quintet, *J*=7 Hz, -NHCH₂C<u>H</u>₂CH₂SPh), 2.72 (2H, t, *J*=7 Hz, -NHCH₂CH₂CH₂C<u>H</u>₂SPh), 2.99 (2H, t, *J*=7 Hz, -NHC<u>H</u>₂CH₂CH₂CH₂SPh) 3.74 (2H, s, -NHC<u>H</u>₂Ar), 3.76 (3H, s, OMe), 3.77 (3H, s, OMe), 6.7-7.4 (8H, m, ArH and SPh), ¹³C-NMR: 29.4 (t), 31.3 (t), 47.7 (t), 49.0 (t), 55.5 (q), 55.6 (q), 111.0 (d), 112.0 (d), 115.8 (d), 125.6 (d), 128.7 (dx2), 128.9 (dx2), 129.5 (s), 136.6 (s), 151.7 (s). 153.3 (s). LRMS *m/z*: 317 (M⁺).

N-(**3**-Methoxyphenyl)methyl-(**3**-phenylsulfanyl)propylamine (**3d**): From 3-methoxybenzaldehyde (**2d**) (0.980 g, 7.2 mmol) and 3-phenylsulfanylamine (1.2g, 7.2 mmol); column chromatography with CHCl₃ gave **3d** (1.736 g, 84%) as yellow oil. IR (film): 1585. ¹H-NMR: 1.83 (2H, quintet, J=7 Hz, -NHCH₂CH₂CH₂SPh), 2.75 (2H, t, J=7 Hz, -NHCH₂CH₂CH₂SPh), 2.99 (2H, t, J=7 Hz, -NHCH₂CH₂CH₂SPh) 3.75 (2H, s, -NHCH₂Ar), 3.80 (3H, s, OMe), 6.7-7.4 (9H, m, ArH and SPh), ¹³C-NMR: 29.5 (t), 31.5 (t), 48.0 (t), 53.8 (t), 55.1 (q), 112.4 (d), 113.5 (d), 120.3 (d), 125.9 (d), 128.8 (dx2), 129.1 (dx2), 129.3 (d), 136.6 (s), 141.9 (s). 159.7 (s). LRMS *m/z*: 287 (M⁺).

N-(4-Methoxyphenyl)methyl-(3-phenylsulfanyl)propylamine (3e): From 4-methoxybenzaldehyde (2e) (0.980 g, 7.2 mmol) and 3-phenylsulfanylamine (1.2g, 7.2 mmol); column chromatography with CHCl₃ gave 3e (1.488 g, 72%) as a yellow oil. IR (film): 1587. ¹H-NMR: 1.82 (2H, quintet, J=7 Hz, -NHCH₂CH₂CH₂SPh), 2.74 (2H, t, J=7 Hz, -NHCH₂CH₂CH₂SPh), 2.99 (2H, t, J=7 Hz, -NHCH₂CH₂CH₂SPh) 3.70 (2H, s, -NHCH₂Ar), 3.79 (3H, s, OMe), 7.1-7.4 (9H, m, ArH and SPh), ¹³C-NMR: 29.4 (t), 31.5 (t), 47.8 (t), 53.2 (t), 55.2 (q), 113.7 (dx2), 125.8 (d), 128.8 (dx2), 129.1 (dx2), 129.2 (dx2), 132.3 (s), 136.6 (s), 158.6 (s). LRMS m/z: 287 (M⁺)

N-(2-Methoxyphenyl)methyl-(3-phenylsulfanyl)propylamine (3f): From 2-methoxybenzaldehyde (2f) (0.980 g, 7.2 mmol) and 3-phenylsulfanylamine (1.2g, 7.2 mmol); column chromatography with CHCl₃ gave 4f (1.570 g, 76%) as a yellow oil. IR (film): 1610. ¹H-NMR: 1.83 (2H, quintet, J=7 Hz, -NHCH₂CH₂CH₂SPh), 2.72 (2H, t, J=7 Hz, -NHCH₂CH₂CH₂SPh), 2.98 (2H, t, J=7 Hz, -NHCH₂CH₂CH₂SPh) 3.77 (2H, s, -NHCH₂Ar), 3.82 (3H, s, OMe), 6.8-7.0 (2H, m, ArH), 7.1-7.4 (7H, m,

ArH and SPh), ¹³C-NMR: 29.5 (t), 31.5 (t), 47.9 (t), 49.1 (t), 55.2 (q), 110.2 (d), 120.3 (d), 125.7 (d), 128.1 (d), 128.3 (d), 128.7 (dx2), 129.0 (dx2), 129.7 (d), 136.7 (s), 157.6 (s). LRMS *m*/*z*: 287 (M⁺).

N-(**3-phenylsulfanyl)propylbenzylamine** (**3g**): From benzaldehyde (**2g**) (0.763 g, 7.2 mmol) and 3-phenylsulfanylamine (1.2g, 7.2 mmol); column chromatography with CHCl₃ gave **3g** (1.091 g, 59 %) as a yellow oil. IR (film): 1583, 1481. ¹H-NMR: 1.84 (2H, quintet, *J*=7 Hz, -NHCH₂C<u>H</u>₂CH₂SPh), 2.76 (2H, t, *J*=7 Hz, -NHCH₂CH₂C<u>H</u>₂SPh), 3.00 (2H, t, *J*=7 Hz, -NHC<u>H</u>₂CH₂CH₂SPh) 3.77 (2H, s, -NHC<u>H</u>₂Ar), 7.0-7.5 (10H, m, Ph and SPh), ¹³C-NMR: 29.4 (t), 31.4(t), 47.9 (t), 53.8 (t), 125.7 (d), 126.8 (d), 128.0 (dx2), 128.3 (dx2), 128.7 (dx2), 129.0 (dx2), 136.6 (s), 140.2 (s). LRMS *m/z*: 257 (M⁺).

Formylation of 3. Typical Procedure. The mixture of formic acid (13.8 g, 0.3 mol) and acetic anhydride (10.2 g, 0.1 mol) was added at rt to **3a** (3.17 g, 10 mmol) and the mixture was heated at 70 °C for 1 h. The reaction mixture was concentrated *in vacuo* and the residue was extracted with CHCl₃. After removal of the solvent, the residue was chromatographed with hexane-ethyl acetate (1:2) to give **4a** (3.45 g, quant.) as a yellow gum.

N-(3,4-Dimethoxyphenyl)methyl-*N*-[(3-phenylsulfany)propyl]fromamide (4a) IR (film): 1669, 1593. ¹H-NMR: 1.7-1.9 (total 2H, m, -NHCH₂CH₂CH₂SPh), 2.8-3.0 (total 2H, m, -NHCH₂CH₂CH₂SPh), 3.2-3.4 (total 2H, m, -NHCH₂CH₂CH₂SPh), 3.84, 3.85, 3.86, 3.88 (total 6H, each s, OMe), 4.30, 4.44 (total 2H, each s, -NHC<u>H</u>₂Ar), 6.7-6.8 (total 3H, m, ArH), 7.2-7.4 (total 5H, m, SPh), 8.19, 8.28 (total 1H, each s, CHO). LRMS *m*/*z*: 345 (M⁺). HRMS *m*/*z* (M⁺): Calcd for C₁₉H₂₃NO₃S: 345.1398. Found: 345.1398 *N*-(3,5-Dimethoxyphenyl)methyl-*N*-[(3-phenylsulfany)propyl]fromamide (4b) From 3b (3.17 g, 10 mmol); column chromatography with hexane-ethyl acetate (2:1) gave 4b (3.45g, quant.) as a yellow gum. IR (film): 1671, 1599. ¹H-NMR: 1.7-1.9 (total 2H, m, -NHCH₂CH₂CH₂SPh), 2.8-2.9 (total 2H, m, -NHCH₂CH₂CH₂SPh) 3.2-3.5 (total 2H, m, -NHCH₂CH₂CH₂SPh), 3.76, 3.77, 3.79, 3.84 (total 6H, each s, OMe), 4.28, 4.43 (total 2H, each s, -NHC<u>H</u>₂Ar), 6.3-6.4 (total 3H, m, ArH), 7.2-7.4 (total 5H, m, SPh), 8.19, 8.25 (total 1H, each s, CHO). LRMS *m*/*z*: 345 (M⁺). HRMS *m*/*z*: 345 (M⁺). HRMS *m*/*z*: 345 (M⁺). HRMS *m*/*z*: 345 (M⁺).

345.1399. Found:345.1423.

N-(2,5-Dimethoxyphenyl)methyl-*N*-[(3-phenylsulfanyl)propyl]formamide (4c) From 3c (3.17 g, 10 mmol); column chromatography with hexane-ethyl acetate (2:1) gave 4c (3.04g, 88%) as a yellow gum. IR (film): 1671, 1590. ¹H-NMR: 1.8-1.9 (total 2H, m, -NHCH₂C<u>H</u>₂CH₂SPh), 2.85 (2H, t, *J*=7 Hz, -NHCH₂C<u>H</u>₂CH₂SPh), 3.2-3.4 (total 2H, m, -NHC<u>H</u>₂CH₂CH₂SPh), 3.73, 3.76 (total 6H, each s, OMe), 4.32, 4.53 (total 2H, each s, -NHC<u>H</u>₂Ar), 6.7-6.8 (total 3H, m, ArH), 7.2-7.3 (total 5H, m, SPh), 8.18, 8.26 (total 1H, each s, CHO). LRMS m/z: 345 (M⁺). HRMS m/z (M⁺): Calcd for C₁₉H₂₃NO₃S: 345.1399. Found:345.1434.

N-(3-Methoxyphenyl)methyl-*N*-[(3-phenylsulfanyl)propyl]formamide (4d) From 3d (2.87 g, 10 mmol); column chromatography with hexane-ethyl acetate (2:1) gave 4d (2.96g, 94%) as a yellow gum. IR (film): 1678, 1601. ¹H-NMR: 1.80 (2H, quintet, J=7 Hz, -NHCH₂CH₂CH₂SPh), 2.83, 2.86 (total 2H, each t, J=7 Hz, -NHCH₂CH₂CH₂CH₂SPh), 3.28, 3.36 (total 2H, each t, J=7 Hz, -NHCH₂CH₂CH₂CH₂SPh), 3.78, 3.79 (total 3H, each s, OMe), 4.32, 4.47 (total 2H, each s, -NHCH₂Ar), 6.7-7.4 (total 9H, m, ArH and SPh), 8.20, 8.27 (total 1H, each s, CHO). LRMS *m/z*: 315 (M⁺). HRMS *m/z* (M⁺): Calcd for C₁₈H₂₁NO₂S: 315.1290. Found: 315.1288.

N-(4-Methoxyphenyl)methyl-*N*-[(3-phenylsulfanyl)propyl]formamide (4e) From 3e (2.87 g, 10 mmol); column chromatography with hexane-ethyl acetate (2:1) gave 4e (2.80 g, 89%) as colorless plates recrystallized from CHCl₃-Et₂O, mp 175-178°C. IR: 1672. ¹H-NMR: 1.79 (2H, quintet, *J*=7 Hz, -NHCH₂CH₂CH₂SPh), 2.85, 2.85 (total 2H, each t, *J*=7 Hz, -NHCH₂CH₂CH₂SPh), 3.27, 3.34 (total 2H, each t, *J*=7 Hz, -NHCH₂CH₂CH₂CH₂CH₂CH₂CH₂SPh), 3.79, 3.80 (total 3H, each s, OMe), 4.29, 4.43 (total 2H, each s, -NHC<u>H₂Ar</u>), 6.8-7.4 (total 9H, m, ArH and SPh), 8.18, 8.27 (total 1H, each s, CHO). LRMS *m/z*: 315 (M⁺). *Anal.* Calcd for C₁₈H₂₁NO₂S: C, 68.55; H, 6.71; N, 4.44. Found: C, 68.53; H, 6.76; N, 4.25.

N-(2-Methoxyphenyl)methyl-*N*-[(3-phenylsulfanyl)propyl]formamide (4f) From 3f (2.87 g, 10 mmol); column chromatography with hexane-ethyl acetate (2:1) gave 4f (2.94g, 90%) as a yellow gum.

IR (film): 1670. ¹H-NMR: 1.7-2.0 (2H, m, -NHCH₂CH₂CH₂SPh), 2.85 (2H, t, J=7 Hz, -NHCH₂CH₂CH₂CH₂SPh), 3.29, 3.34 (total 2H, each t, J=7 Hz, -NHCH₂CH₂CH₂CH₂SPh), 3.80 (3H, each s, OMe), 4.35, 4.56 (total 2H, each s, -NHCH₂Ar), 6.8-7.5 (total 9H, m, ArH and SPh), 8.18, 8.27 (total 1H, each s, CHO). LRMS m/z: 315 (M⁺). HRMS m/z (M⁺): Calcd for C₁₈H₂₁NO₂S: 315.1290. Found: 315.1279.

N-Benzyl-*N*-[(3-phenylsulfanyl)propyl]formamide (4g) From 3g (2.57 g, 10 mmol); column chromatography with hexane-ethyl acetate (2:1) gave 4g (2.565g, 90%) as a yellow gum. IR (film): 1672. ¹H-NMR: 1.79 (2H, quintet, J=7 Hz, -NHCH₂CH₂CH₂SPh), 2.83, 2.86 (total 2H, each t, J=7 Hz, -NHCH₂CH₂CH₂SPh), 3.29, 3.36 (total 2H, each t, J=7 Hz, -NHCH₂CH₂CH₂CH₂SPh), 4.35, 4.50 (total 2H, each s, -NHCH₂Ar), 7.1-7.5 (10H, m, Ph and SPh), 8.20, 8.28 (total 1H, each s, CHO). LRMS m/z: 285 (M⁺). HRMS m/z (M⁺): Calcd for C₁₂H₁₉NOS: 285.1184. Found: 285.1177

Oxidation of 4a with NaIO₄. Typical Procedure. NaIO₄ (6.42g, 30 mmol) in H₂O (35 mL) was added to a solution of **4a** (6.9g, 20 mmol) in MeOH (70 mL) and stirred at rt for 5 h. After removal of inorganic precipitates by filtration, the filtrate was concentrated *in vacuo*. The residue was extracted with CHCl₃. The product was purified by column chromatography with ethyl acetate to give **5a** (6.137 g, 84%) as a yellow gum.

N-(3,4-Dimethoxyphenyl)methyl-*N*-[(3-phenylsulfinyl)propyl]formamide (5a) IR (film): 1666, 1025. ¹H-NMR: 1.8-2.1 (total 2H, m, -NHCH₂C<u>H</u>₂CH₂SPh), 2.5-2.8 (total 2H, m, -NHCH₂CH₂C<u>H</u>₂SPh), 3.1-3.5 (total 2H, m, -NHC<u>H</u>₂CH₂CH₂SPh), 3.86, 3.87, 4.22 (total 6H, each s, OMe), 4.31, 4.41 (total 2H, each s, -NHC<u>H</u>₂Ar), 6.6-6.9 (total 3H, m, ArH), 7.4-7.6 (total 5H, m, SPh), 8.14, 8.28 (total 1H, each s, CHO). LRMS m/z: 361 (M⁺).

N-(3,5-Dimethoxyphenyl)methyl-*N*-[(3-phenylsulfinyl)propyl]formamide (5b) From 4b (3.45 g, 10 mmol); column chromatography with ethyl acetate gave 5b (3.1g, 86%) as a yellow gum. IR (film): 1668, 1047. ¹H-NMR: 1.8-2.1 (total 2H, m, -NHCH₂CH₂CH₂SPh), 2.5-2.9 (total 2H, m, -NHCH₂CH₂CH₂SPh), 3.2-3.5 (total 2H, m, -NHCH₂CH₂CH₂SPh), 3.76, 3.78 (total 6H, each s, OMe), 4.2-4.5 (total 2H, m,

-NHC<u>H</u>₂Ar), 6.2-6.4 (total 3H, m, ArH), 7.4-7.7 (total 5H, m, SPh), 8.15, 8.25 (total 1H, each s, CHO). LRMS *m*/*z*: 361 (M⁺).

N-(2,5-Dimethoxyphenyl)methyl-*N*-[(3-phenylsulfinyl)propyl]fromamide (5c) From 4c (3.45 g, 10 mmol); column chromatography with ethyl acetate gave 5c (3.45g, 95%) as a yellow gum. IR (film): 1669, 1048. ¹H-NMR: 1.8-2.0 (total 2H, m, -NHCH₂CH₂CH₂SPh), 2.6-2.8 (total 2H, m, -NHCH₂CH₂CH₂SPh), 3.2-3.5 (total 2H, m, -NHCH₂CH₂CH₂SPh), 3.73, 3.76 (total 6H, each s, OMe), 4.32, 4.50 (total 2H, each s, -NHCH₂Ar), 6.7-6.8 (total 3H, m, ArH), 7.4-7.6 (total 5H, m, SPh), 8.11, 8.25 (total 1H, each s, CHO). LRMS m/z: 361 (M⁺).

N-(**3**-Methoxyphenyl)methyl-*N*-[(**3**-phenylsulfinyl)propyl]fromamide (**5**d) From **4**d (6.3 g, 20 mmol); column chromatography with ethyl acetate gave **5**d (4.965, 75%) as a yellow gum. IR (film): 1664, 1045. ¹H-NMR: 1.7-2.3 (2H, quintet, J=7 Hz, -NHCH₂CH₂CH₂SPh), 2.5-2.9 (total 2H, m, -NHCH₂CH₂CH₂CH₂SPh), 3.1-3.5 (total 2H, m, -NHCH₂CH₂CH₂SPh), 3.78, 3.80 (total 3H, each s, OMe), 4.2-4.6 (total 2H, m, -NHCH₂Ar), 6.7-7.8 (total 9H, m, ArH and SPh), 8.15, 8.27 (total 1H, each s, CHO). LRMS m/z: 315 (M⁺-16).

N-(**4**-Methoxyphenyl)methyl-*N*-[(**3**-phenylsulfinyl)propyl]fromamide (**5**e) From **4e** (6.3 g, 20 mmol); column chromatography with ethyl acetate gave **5e** (5.43 g, 82%) as a colorless gum. IR: 1664, 1033. ¹H-NMR: 1.7-2.0 (total 2H, m, -NHCH₂CH₂CH₂SPh), 2.6-2.9 (total 2H, m, -NHCH₂CH₂CH₂CH₂SPh), 3.2-3.4 (total 2H, m, -NHCH₂CH₂CH₂SPh), 3.79, 3.81 (total 3H, each s, OMe), 4.2-4.6 (total 2H, m, -NHCH₂Ar), 6.7-7.4 (total 9H, m, ArH and SPh), 8.13, 8.27 (total 1H, each s, CHO). LRMS m/z: 286 (M⁺-45).

N-(2-Methoxyphenyl)methyl-N-[(3-phenylsulfinyl)propyl]fromamide (5f) From 4f (6.3 g, 20 mmol); column chromatography with ethyl acetate gave 5f (4.90g, 74%) as a yellow gum. IR (film): 1664, 1045. ¹H-NMR: 1.7-2.1 (2H, m, -NHCH₂CH₂CH₂SPh), 2.6-2.9 (2H, m, -NHCH₂CH₂CH₂SPh), 3.0-3.5 (total 2H, m, -NHCH₂CH₂CH₂SPh), 3.81 (3H, s, OMe), 4.35, 4.51 (total 2H, each s, -NHCH₂Ar), 6.8-7.7

(total 9H, m, ArH and SPh), 8.12, 8.27 (total 1H. each s, CHO). LRMS *m/z*: 286 (M⁺-45).

N-Benzyl-*N*-[(3-phenylsulfinyl)propyl]fromamide (5g) From 4g (7.5 g, 26.3 mmol); column chromatography with ethyl acetate gave 5g (6.71g, 85%) as a colorless gum. IR (film): 1670, 1045. ¹H-NMR: 1.7-2.0 (total 2H, m, -NHCH₂C<u>H</u>₂CH₂SPh), 2.4-3.0 (total 2H, m, -NHCH₂CH₂C<u>H</u>₂SPh), 3.1-3.5 (total 2H, m, -NHC<u>H</u>₂CH₂CH₂SPh), 42-4.5 (total 2H, m, -NHC<u>H</u>₂Ar), 7.1-7.7 (total10H, m, Ph and SPh), 8.16, 8.28 (total 1H, each s, CHO). LRMS m/z: 256 (M⁺-45).

Pummerer Reaction of 5a. Typical Procedure.

i)Method A. TFAA (1.586 g, 7.55 mmol) was added to a solution of **5a** (500 mg, 1.51 mmol) in benzene (50 mL) at rt, and the mixture was stirred for 4 h under an argon atmosphere. After removal of the solvent *in vacuo*, the product was purified by column chromatography with ethyl acetate-hexane (1:4) to give **6a** (260 mg, 56%) and **7a** (146 mg, 31%).

ii) Method B. TFAA (582 mg, 2.8 mmol) was added to a solution of **5a** (200 mg, 0.55 mmol) in benzene (20 mL) at rt, and the mixture was stirred for 30 min under an argon atmosphere. To this solution $BF_3 \cdot Et_2O$ (394 mg, 2.8 mmol) was added, and the mixture was stirred at rt for 45 min. After removal of the solvent *in vacuo*, the residue was treated with 5% NaHCO₃ and extracted with CHCl₃. The residual oil was purified by column chromatography with ethyl acetate to give **6a** (125 mg, 66%) and **4a** (9 mg, 5%).

2-Formyl-7,8-dimethoxy-5-phenylsulfanyl-2,3,4,5-tetrahydro-1*H***-2-benzazepine** (6a) Colorless gum. IR(film): 1668. ¹H-NMR: 2.0-2.3 (total 2H, m, 4-H), 3.67, 3.88 (total 6H, each s, OMe), 3.4-5.1 (total 5H, m, 1-H, 3-H, 5-H), 6.41, 6.44, 6.69, 6.89 (total 2H, each s, ArH), 7.2-7.3 (total 5H, m, SPh), 8.05, 8.15 (total 1H, each s, CHO). LRMS m/z: 343 (M⁺). HRMS m/z (M⁺): Calcd for C₁₉H₂₁NO₃S: 343.1240. Found: 343.1227.

N-[(3,5-Dimethoxyphenyl)methyl]-*N*-[(3-phenylsulfanyl)-2-propenyl]formamide (7a): Yellow gum. IR (film): 1671. ¹H-NMR: 3.80, 3.83, 3.84, 3.86, 3.87 (total 6H, each s, OMe), 3.7-4.2 (total 2H, m, -CH₂CH=), 4.33, 4.41, 4.46 (total 2H, each s, -CH₂Ar), 5.4-5.8 (total 1H, m, -CH=CH-), 6.1-6.6 (total 1H, m, -CH=CH=), 6.6-6.9 (total 3H, m, -ArH), 7.2-7.5 (total 5H, m, SPh), 8.20, 8.26, 8.30, 8.32 (total 1H. each s, CHO). LRMS m/z: 343 (M⁺). HRMS m/z (M⁺): Calcd for C₁₉H₂₁NO₃S: 343.1239. Found: 343.1223.

Pummerer Reaction of 5b.

i) Method A. **5b** (100 mg, 0.28 mmol) gave **6b** (12 mg, 13%).

ii) Method B. **5b** (1g, 2.8 mmol) gave **6b** (578 mg, 61%).

2-Formyl-6,8-dimethoxy-5-phenylsulfanyl-2,3,4,5-tetrahydro-1*H***-2-benzazepine** (**6b**) Pale yellow gum. IR(film): 1671, 1604. ¹H-NMR: 1.8-2.2 (total 2H, m, 4-H), 3.64, 3.80 (total 6H, each s, OMe), 3.8-5.1 (total 4H, m, 1-H, 3-H), 5.4-5.5 (total 1H, m, 5-H), 6.28, 63.1 (total 1H, each s, 7-H), 6.53-6.55 (total 1H, each s, 9-H), 7.2-7.5 (total 5H, m, SPh), 8.04, 8.13 (total 1H. each s, CHO). LRMS *m/z*: 343 (M⁺).

Pummerer Reaction of 5c.

Method B. 5c (500 mg, 1.4 mmol) gave 6c (214mg, 45%).

2-Formyl-6,9-dimethoxy-5-phenylsulfanyl-2,3,4,5-tetrahydro-1*H***-2-benzazepine (6c)** Pale yellow gum. IR(film): 1668, 1593. ¹H-NMR: 3.5-4.3 (total 4H, m, 3-H, 4-H), 3.62, 3.64, 3.80, 3.86 (total 6H, each s, OMe), 4.53, 4.71 (total 1H, each s, 1-H), 5.10, 5.27 (total 1H, each bs, 1-H), 5.4-5. (total 1H, m, 5-H), 6.7-6.8 (total 2H, m, 7-H and 8-H), 7.2-7.5 (total 5H, m, SPh), 8.07, 8.11 (total 1H. each s, CHO). LRMS m/z: 343 (M⁺). HRMS m/z (M⁺): Calcd for C₁₉H₂₁NO₃S: 343.1242. Found: 343.1288.

Pummerer Reaction of 5d.

i) Method A. **5d** (125 mg, 0.38 mmol) gave **6d** (15 mg, 13%).

ii) Method B. **5d** (3 g, 9.06 mmol) gave **6d** (2.2 g, 78%).

2-Formyl-8-methoxy-5-phenylsulfanyl-2,3,4,5-tetrahydro-1*H***-2-benzazepine (6d)** Pale yellow gum. IR(film): 1670. ¹H-NMR: 2.0-2.3 (total 2H, m, 4-H), 3.5-3.9 (total 1H, m, 5-H), 3.78 (3H, s, OMe), 4.3-5.1 (total 4H, m, 1-H, 3-H), 6.5-6.9 (total 3H, m, ArH), 7.2-7.4 (total 5H, m, SPh), 8.04, 8.13 (total 1H. each s, CHO). LRMS *m*/*z*: 313 (M⁺). HRMS *m*/*z* (M⁺): Calcd for C₁₈H₁₉NO₂S: 313.1133. Found: 313.1101.

Pummerer Reaction of 5e.

Method B. 5e (500 mg, 1.51 mmol) gave 8e (68 mg, 21%).

N-(**4**-Methoxyphenyl)methyl-*N*-[**3**,**3**-di(phenylsulfanyl)propyl]formamide (8e) Yellow gum. IR (film): 1670, 1512. ¹H-NMR: 1.97 (2H, brq, J=7 Hz, -NHCH₂CH₂CH(SPh)₂), 3.2-3.6 (total 2H, m, -NHCH₂CH₂CH(SPh)₂), 3.79, 3.80 (total 3H, each s, OMe), 4.1-4.4 (total 3H, m, -NHCH₂Ar and -CH(SPh)₂), 6.7-7.6 (total 14H, m, ArH and SPhx2), 8.16, 8.23 (total 1H. each s, CHO). LRMS *m*/*z*: 423 (M⁺). Pummerer Reaction of 5f.

Method B. 5f (500 mg, 1.51 mmol) gave 8f (107 mg, 33%).

N-(2-Methoxyphenyl)methyl-*N*-[3,3-di(phenylsulfany)propyl]fromamide (8f) IR (film): 1670. ¹H-NMR: 1.6-2.2 (2H, m, -NHCH₂C<u>H</u>₂CH(SPh)₂), 3.44 (2H, brq, J=7 Hz, -NHC<u>H</u>₂CH₂CH(SPh)₂), 3.76, 3.79 (total 3H, each s, OMe), 4.1-4.7 (total 3H, m, -NHC<u>H</u>₂Ar and -C<u>H</u>(SPh)₂), 6.8-7.6 (total 14H, m, ArH and SPhx2), 8.16, 8.24 (total 1H. each s, CHO). LRMS m/z: 423 (M⁺).

Reductive Desulfulization of 6. Typical Procedure. To a stirred suspension of 6a (1.81 g, 5.3 mmol) and NiCl₂•6H₂O (4.40g, 18.5 mmol) in MeOH-THF (3:1, 80 mL) was added NaBH₄ (2.11 g, 55.5mmol) by portions at 0°C. After the addition completed, stirring was continued for 20 min. The reaction mixture was filtered and the filtrate was concentrated *in vacuo*. The products were purified by column chromatography with ethyl acetate-hexane (1:1) and recrystallized from ethyl acetate-Et₂O to give **9a** (998 mg, 80%) as colorless prisms, mp 130-132 °C.

2-Formyl-7,8-dimethoxy-2,3,4,5-tetrahydro-1*H***-2-benzazepine** (**9a**). IR: 1666, 1604. ¹H-NMR: 1.7-1.9 (total 2H, m, 4-H), 2.8-3.0 (total 2H, m, 5-H), 3.5-3.8 (total 2H, m, 3-H), 3.83, 3.84 (total 6H, each s, OMe), 4.36, 4.46 (total 2H, each s, 1-H), 6.66, 6.89 (total 2H, each s, ArH), 7.98, 8.12 (total 1H, each s, CHO), LRMS *m*/*z*: 235 (M⁺). HRMS *m*/*z* (M⁺): Calcd for C₁₃H₁₇NO₃: 235.1209. Found: 235.1208.

2-Formyl-6,8-dimethoxy-2,3,4,5-tetrahydro-1*H*-2-benzazepine (9b). From 6b (578 mg, 1.7 mmol); column chromatography with ethyl acetate-hexane (1:1) gave 9b (297 mg, 75%) as colorless prisms

recrystallized from ethyl acetate-Et₂O, mp 83-85 °C. IR: 1664. ¹H-NMR: 1.6-1.9 (total 2H, m, 4-H), 2.9-3.2 (total 2H, m, 5-H), 3.5-3.7 (total 2H, m, 3-H), 3.77, 3.78, 3.80 (total 6H, each s, OMe), 4.38, 4.50 (total 2H, each s, 1-H), 6.3-6.6 (total 2H, m, ArH), 8.00, 8.13 (total 1H, each s, CHO), LRMS m/z: 235 (M⁺).

2-Formyl-6,9-dimethoxy-2,3,4,5-tetrahydro-1*H***-2-benzazepine** (**9c**). From **6c** (963 mg, 2.8 mmol); column chromatography with ethyl acetate-hexane (1:1) gave **9c** (338 mg, 53%) as pale yellow prisms recrystallized from ethyl acetate-Et₂O, mp 83-88 °C. IR: 1670, 1596. ¹H-NMR: 1.7-1.9 (total 2H, m, 4-H), 2.9-3.1 (total 2H, m, 5-H), 3.4-3.63 (total 2H, m, 3-H), 3.76, 3.80, 3.84 (total 6H, each s, OMe), 4.59, 4.73 (total 2H, each s, 1-H), 6.7 (total 2H, m, ArH), 8.02, 8.12 (total 1H, each s, CHO), LRMS m/z: 235 (M⁺). HRMS m/z (M⁺): Calcd for C₁₃H₁₇NO₃: 235.1206. Found: 235.1298.

2-Formyl-8-methoxy-2,3,4,5-tetrahydro-1*H***-2-benzazepine** (**9d**). From **6d** (2 g, 6.39 mmol); column chromatography with ethyl acetate-hexane (1:1) gave **9d** (935 mg, 71%) as a pale yellow gum. IR (film): 1670. ¹H-NMR: 1.6-2.0 (2H, m, 4-H), 2.92 (2H, t, *J*=6 Hz, 5-H), 3.5-4.0 (total 2H, m, 3-H), 3.78 (3H, s, OMe), 4.59, 4.73 (total 2H, each s, 1-H), 6.7 (3H, m, ArH), 8.02, 8.12 (total 1H, each s, CHO), LRMS m/z: 205 (M⁺). HRMS m/z (M⁺): Calcd for C₁₂H₁₅NO₂: 205.1103. Found: 205.1121.

Hydrolysis of 9a. Typical Procedure. A solution of **9a** (300 mg, 1.3 mmol) in EtOH (5 mL) and 10% NaOH (5 mL) was refluxed for 1 h. The reaction mixture was concentrated *in vacuo* and the residue was extracted with CHCl₃. The product was purified by column chromatography with ethyl acetate to give **10a** (259 mg, 98%) as a pale yellow gum.¹¹

7,8-Dimethoxy-2,3,4,5-tetrahydro-1*H***-2-benzazepine** (**10a**).^{9,10} IR (film): 1606. ¹H-NMR: 1.6-1.9 (2H, m, 4-H), 2.8-3.0 (2H, m, 5-H), 3.1-3.3 (2H, m, 3-H), 3.85 (3H, s, OMe), 3.86 (3H, s, OMe), 3.88 (2H, s, 1-H), 6.68 (1H, s, ArH), 6.70 (1H, s, ArH). ¹³C-NMR: 30.3 (t), 34.9 (t), 52.8 (t), 53.9 (t), 55.1 (qx2), 111.9 (d), 112.7 (d), 134.3 (s), 134.5 (s), 145.7 (s), 146.4 (s). LRMS *m/z*: 207 (M). HRMS *m/z* (M⁺): Calcd for C₁₂H₁₇NO₂: 207.1260. Found: 207.1290.

6,8-Dimethoxy-2,3,4,5-tetrahydro-1H-2-benzazepine (10b). From 9b (297 mg, 1.3 mmol); column

chromatography with ethyl acetate gave **10b** (169 mg, 65%) as colorless prisms recrystallized from ethyl acetate-hexane, mp 68-70 °C. IR: 1587. ¹H-NMR: 1.5-1.8 (2H, m, 4-H), 2.8-3.0 (2H, m, 5-H), 3.1-3.2 (2H, m, 3-H), 3.78 (6H, s, OMe), 3.88 (2H, s, 1-H), 6.31 (1H, d, J=2 Hz, ArH), 6.36(1H, d, J=2 Hz, ArH). ¹³C-NMR: 24.5 (t), 30.4 (t), 53.6 (t), 55.2 (t), 55.3 (q), 55.8 (q), 97.2 (d), 105.3 (d), 123.3 (s), 145.1 (s), 157.6 (s), 158.1 (s). LRMS m/z: 207 (M⁺). HRMS m/z (M⁺): Calcd for C₁₂H₁₇NO₂: 207.1256. Found: 207.1238.

6,9-Dimethoxy-2,3,4,5-tetrahydro-1*H***-2-benzazepine** (**10c**). From **9c** (100 mg, 0.43 mmol); column chromatography with ethyl acetate gave **10c** (82 mg, 85%) as colorless prisms recrystallized from ethyl acetate-hexane, mp 58-60 °C. IR: 1594. ¹H-NMR: 1.6-1.7 (2H, m, 4-H), 3.0 (2H, m, 5-H), 3.2 (2H, m, 3-H), 3.75 (6H, s, OMe), 4.07 (2H, s, 1-H), 6.66 (1H, d, J=9 Hz, ArH), 6.70 (1H, d, J=9 Hz, ArH). ¹³C-NMR: 25.3 (t), 29.3 (t), 44.6 (t), 53.4 (t), 56.3 (q), 56.6 (q), 109.2 (d), 110.6 (d), 132.2 (s), 133.5 (s), 150.7 (s), 150.9 (s). LRMS m/z: 207 (M⁺). HRMS m/z (M⁺): Calcd for C₁₂H₁₇NO₂: 207.1258. Found: 207.1253

8-Methoxy-2,3,4,5-tetrahydro-1*H*-2-benzazepine (10d). From 9d (300 mg, 1.46 mmol); column chromatography with ethyl acetate gave 10d (240 mg, 93%) as colorless needles recrystallized from ethyl acetate-hexane, mp 39-41 °C. IR: 1610. ¹H-NMR: 1.68 (2H, m, 4-H), 2.89 (2H, t, *J*=5 Hz, 5-H), 3.19 (2H, t, *J*=5 Hz, 3-H), 3.77 (3H, s, OMe), 3.88 (2H, s, 1-H), 6.5-7.2 (3H, m, ArH). ¹³C-NMR: 31.1 (t), 35.1 (t), 53.4 (t), 55.1 (q), 111.2 (d), 114.4 (d), 130.0 (d), 134.8 (s), 143.8 (s), 157.7 (s). LRMS *m/z*: 178 (M⁺). Reduction of 9a with LiAlH₄. Typical Procedure. LiAlH₄ (97 mg, 2.6 mmol) was added to the solution of 9a (300 mg, 1.3 mmol) in dry THF (15 mL) under ice-cooling, and the mixture was refluxed for 1 h. Et₂O saturated with water was added to the reaction mixture, and insoluble material was filtered off. The filtrate was concentrated *in vacuo* and the residue was extracted with CHCl₃. The product was purified by column chromatography with ethyl acetate to give 11a (258 mg, 91%) as a pale yellow gum.

7,8-Dimethoxy-2-methyl-2,3,4,5-tetrahydro-1*H*-2-benzazepine (11a). IR(film): 1606. ¹H-NMR:

1.6-1.9 (2H, m, 4-H), 2.32 (3H, s, NMe), 2.7-3.0 (4H, m, 5-H and 3-H), 3.49 (2H, s, 1-H), 3.83 (6H, s, OMe), 6.67 (1H, s, ArH), 6.68 (1H, s, ArH). ¹³C-NMR: 25.7 (t), 34.7 (t), 43.2 (q), 55.3 (q), 55.4 (q), 60.8 (t), 61.4 (t), 112.4 (d), 113.4 (d), 130.7 (s), 134.6 (s), 146.0 (s), 146.9 (s). LRMS m/z: 221 (M⁺). HRMS m/z (M⁺): Calcd for C₁₃H₁₉NO₂: 221.1414. Found: 221.1399.

6,8-Dimethoxy-2-methyl-2,3,4,5-tetrahydro-1*H***-2-benzazepine (11b).** From **9b** (256 mg, 1.3 mmol); column chromatography with ethyl acetate gave **11b** (240 mg, 99%) as a colorless gum. IR(film): 1606. ¹H-NMR: 1.6-1.8 (2H, m, 4-H), 2.31 (3H, s, NMe), 2.8-3.0 (4H, m, 3-H and 5-H), 3.75 (2H, s, 1-H), 3.777 (3H, s, OMe), 3.782 (3H, s, OMe), 6.33 (1H, d, *J*=2 Hz, ArH), 6.36 (1H, d, *J*=2 Hz, ArH). ¹³C-NMR: 24.3 (t), 25.5 (t), 43.5 (q), 55.3 (q), 55.8 (q), 61.4 (t), 62.3 (t), 97.4 (d), 106.7 (d), 123.4 (s), 141.6 (s), 157.2 (s), 158.1 (s). LRMS *m/z*: 221 (M⁺). HRMS *m/z* (M⁺): Calcd for C₁₃H₁₉NO₂: 221.1416. Found: 221.1454.

6,8-Dimethoxy-2-methyl-2,3,4,5-tetrahydro-1*H***-2-benzazepine (11c).** From **9c** (500 mg, 2.1 mmol); column chromatography with ethyl acetate gave **11c** (435 mg, 93%) as a colorless gum. IR(film): 1594. ¹H-NMR: 1.6-1.7 (2H, m, 4-H), 2.27 (3H, s, NMe), 2.8-2.9 (4H, m, 3-H and 5-H), 3.657 (3H, s, OMe), 3.664 (3H, s, OMe), 3.79 (2H, s, 1-H), 6.54 (1H, d, *J*=9 Hz, ArH), 6.66 (1H, d, *J*=9 Hz, ArH). ¹³C-NMR: 24.8 (t), 25.9 (t), 44.9 (q), 52.0 (t), 56.1 (q), 56.5 (q), 61.9 (t), 108.8 (d), 110.5 (d), 129.2 (s), 133.5 (s), 150.5 (s), 151.4 (s). LRMS *m*/*z*: 221 (M⁺).

8-Methoxy-2-methyl-2,3,4,5-tetrahydro-1*H***-2-benzazepine** (**11d**). From **9d** (100 mg, 0.49 mmol); column chromatography with ethyl acetate gave **11d** (87 mg, 94%) as a colorless gum. IR (film): 1608. ¹H-NMR: 1.5-1.8 (2H, m, 4-H), 2.21 (3H, s, NMe), 2.72 (2H, t, *J*=6 Hz, 5-H), 2.90 (2H, t, *J*=6 Hz, 3-H), 3.65 (2H, s, 1-H), 3.67 (3H, s, OMe), 6.4-7.0 (3H, m, ArH). ¹³C-NMR: 25.8 (t), 34.7 (t), 43.0 (q), 55.1 (q), 61.1 (t), 62.1 (t), 111.5 (d), 115.8 (d), 129.5 (d), 134.8 (s), 140.1 (s), 157.7 (s). LRMS *m/z*: 191 (M⁺).

ACKNOWLEDGMENTS

This work was supported by a Grant-in-Aid for Scientic Research (No. 11672115) from the Ministry of

Education, Science, Sports and Culture of Japan.

REFERENCES

- 1. M. Kennedy and M. McKervey, "Comprehensive Organic Chemistry," Vol. 7, ed. by B. M. Trost and I. Fleming, Pergamon, Oxford, 1991, pp 193-216.
- 2. A. Padwa, D. E. Jr. Gunn, and H. Osterhout, Synthesis, 1997, 1353.
- 3. (a) T. Shinohara, J. Toda, and T. Sano, *Chem. Pharm. Bull.* 1997, 45, 813. (b) T. Shinohara, A. Takeda, J. Toda, Y. Ueda, M. Kohno, and T. Sano, *ibid.* 1998, 46, 918. (c) T. Shinohara, A. Takeda, J. Toda, N. Terasawa, and T. Sano, *Heterocycles*, 1997, 46, 555. (d) T. Shinohara, A. Takeda, J. Toda, and T. Sano, *Chem. Pharm. Bull.* 1998, 46, 430.
- 4. J. Toda, M. Sakagami, and T. Sano, Chem. Pharm. Bull., 1999, 47, 1269.
- (a) H. Ishibashi, S. Harada, K. Sato, M. Ikeda, S. Akai, and Y. Tamura, *Chem. Pharm. Bull.*, 1985, 33, 5278.
 (b) H. Ishibashi, K. Sato, and M. Ikeda, *J. Chem. Soc.*, *Perkin Trans. I*, 1985, 605.
 (c) J. Toda, Y. Niimura, K. Takeda, T. Sano, and Y. Tsuda, *Chem. Pharm. Bull.*, 1998, 46, 906.
 (d) J. Toda, Y. Niimura, T. Sano, and Y. Tsuda, *Heterocycles*, 1998, 48, 1599.
- 6. T. Shinohara, A. Takeda, J. Toda, and T. Sano, *Heterocycles*, 1998, 48, 981.
- J. Toda, M. Sakagami, Y. Goan, M. Simakata, T. Saitoh, Y. Horiguchi, and T. Sano, *Chem. Pharm. Bull.*, 2000, in press.
- 8. J. Toda, T, Ichikawa, T. Saitoh, Y. Horiguchi, and T. Sano, Heterocycles, 2000, 53, 2009.
- C. J. W. Walpole, S. Bevan, G. Bovermann, J. J. Boelsterli, R. Brecenridge, J. W. Davies, G. A. Hughes, I. James, L. Oberer, J. Winter, and R. Wrigglesworth, *J. Med. Chem.*, 1994, **37**, 1942.
- 10. D. A. Alsono, A. Costa, B. Mancheno, and C. Najera, Tetrahedron, 1997, 53, 4791.
- 11. The physical data were not described in reference 9 and 10.